The market size of the Global Newborn Screening Market in the year 2021 is valued at 879.80 million and is predicted to reach 1993.56 million by the year 2030 at an 9.6% CAGR during the forecast period.
During the newborn screening, conditions that may have an impact on a child's long-term health or survival are discovered. Children can achieve their full potential when they receive early identification, diagnosis, and intervention. Before being released from a hospital or birthing centre, millions of babies in the U.S. undergo routine screening for certain genetic, endocrine, and metabolic disorders using a few drops of blood from the newborn's heel.
The newborn screening market is expected to be significantly influenced by an expanding neonatal population, an increase in the prevalence of congenital illnesses in infants, favorable government policies and laws, and technical improvements. One of the leading market drivers is the increase in the number of newborns. The world population metre is increasing, which further boosts the market. Organizations like the WHO, CDC, Healthy Newborn Network, etc., are working to inform parents about potential problems and associated testing methods to stop this number from rising. Furthermore, due to COVID-19, there was a decline in the market in 2020, but the market rebounded in 2021 with increasing awareness among the people regarding child safety and preventive measures.
The newborn screening market is segmented by technology into pulse oximetry, tandem mass spectrometry, enzyme and DNA-based tests, and electrophoresis. Tandem mass spectrometry (TMS), a cutting-edge analytical tool used in labs to examine bodily fluids and other pollutants, can assess these substances. Due to its strong demand, cost-effectiveness, broad applicability, and technological advancements, tandem mass spectrometry has the highest share. Due to its superior ability to diagnose a variety of problems in a single operation, tandem spectroscopy (MS/MS) is also anticipated to rise in the coming years.
By products, the market is divided into instruments, reagents, assay kits and others. By Application, the market is divided into dry blood spot tests, critical congenital heart disease, hearing screens and others. Regionally, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America region is anticipated to dominate this market over the forecast years.
The prominent players in the Functional Beverages industry include Perkinelmer, Inc., Waters Corporation, Natus Medical Incorporated, Ab Sciex LLC, Masimo Corporation, Bio-Rad Laboratories, Inc., Covidien Plc, Ge Healthcare, Trivitron Healthcare and Agilent Technologies Inc and other prominent players.
Chapter 2. Executive Summary
